Cargando…
Treatment-Resistant Depression. Part A /
Major depressive disorder (MDD) is a common but deteriorating illness worldwide with high comorbidity. The World Health Organization has estimated that MDD would be the leading cause of human disability by 2030. However, many patients with depression fail to respond to antidepressant treatment. Such...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam, Netherlands ; Oxford, United Kingdom ; Cambridge MA :
Elsevier,
2023.
|
| Edición: | First edition. |
| Colección: | Progress in brain research ;
v. 278. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a22000007i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_on1390569133 | ||
| 003 | OCoLC | ||
| 005 | 20231120010747.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 230708t20232023caub o 000 0 eng d | ||
| 040 | |a SFB |b eng |e rda |e pn |c SFB |d EBLCP |d GZM |d BRX |d OPELS |d YDX | ||
| 066 | |c (S | ||
| 019 | |a 1389613565 |a 1389630375 |a 1389632148 | ||
| 020 | |z 9780323957786 | ||
| 020 | |z 0323957781 | ||
| 020 | |a 9780323957793 |q electronic book | ||
| 020 | |a 032395779X |q electronic book | ||
| 035 | |a (OCoLC)1390569133 |z (OCoLC)1389613565 |z (OCoLC)1389630375 |z (OCoLC)1389632148 | ||
| 050 | 4 | |a RC537 |b .L52 2023 | |
| 082 | 0 | 4 | |a 616.852706 |2 23/eng/20230821 |
| 100 | 1 | |a Li, Cheng-Ta. | |
| 245 | 1 | 0 | |a Treatment-Resistant Depression. |n Part A / |c edited by Cheng-Ta Li and Cheng Chih-Ming. |
| 250 | |a First edition. | ||
| 264 | 1 | |a Amsterdam, Netherlands ; |a Oxford, United Kingdom ; |a Cambridge MA : |b Elsevier, |c 2023. | |
| 264 | 4 | |c �2023 | |
| 300 | |a 1 online resource (176 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Progress in brain research ; |v .278 | |
| 505 | 0 | |a Intro -- Treatment-Resistant Depression Part A -- Copyright -- Contributors -- Contents -- Preface -- Chapter 1: Overview of treatment-resistant depression -- Abstract -- Keywords -- 1. Rationale for defining treatment-resistant depression and solving unsolved problems -- 2. Definition of an adequate antidepressant trial and TRD -- 2.1. What is a failed response to an adequate antidepressant trial? -- 2.2. One or two failed adequate antidepressant trials for TRD -- 3. Epidemiology and poor outcomes of TRD -- 3.1. Epidemiology of TRD, with a special focus on adult patients -- 3.2. Poorer clinical outcomes and higher burden associated with TRD -- 4. Different staging models for TRD -- 5. Treatment strategies for adult patients with TRD -- 5.1. Evidence-based treatment guidelines for TRD -- 5.2. Switching and augmentation or combination -- 5.3. Psychotherapeutic interventions -- 5.4. Neurostimulation, glutamatergic compounds, and other experimental agents -- References -- Chapter 2: Genetics of antidepressant response and treatment-resistant depression -- Abstract -- Keywords -- 1. Introduction -- 2. Candidate gene association studies -- 2.1. Glutamatergic pathway -- 2.2. Serotonergic neurotransmission -- 2.3. Hypothalamic-pituitary-adrenal axis -- 2.4. Cytochrome P450 -- 2.5. Other candidate gene association studies -- 2.6. Examining gene-gene and gene-environment interactions in antidepressant response -- 3. Genome-wide association studies -- 3.1. Polygenic risk score -- 4. Whole genome sequencing -- 5. Other genetic variations -- 6. Epigenetics -- 7. Discussion -- References -- Chapter 3: Neuroinflammation through the vagus nerve-dependent gut-microbiota-brain axis in tre -- Abstract -- Keywords -- 1. Introduction -- 2. The gut-microbiota-brain axis in depression and fecal microbiota transplantation -- 2.1. Gut-microbiota-brain axis in depression. | |
| 505 | 8 | |a Chapter 5: Functional MRI markers for treatment-resistant depression: Insights and challenges -- Abstract -- Keywords -- 1. Introduction -- 2. Functional magnetic resonance imaging and TRD -- 3. Brain connectivity and activity in TRD -- 3.1. Evidence from rs-fMRI studies -- 3.2. Evidence from task-based fMRI -- 3.3. TRD compared to major depressive disorder (MDD) -- 3.4. TRD brain connectivity and activity in response to interventions -- 3.5. Ketamine-Evidence from rs-fMRI studies -- 3.6. Ketamine-Evidence from task-based fMRI studies -- 3.7. Psilocybin-Evidence from fMRI studies -- 3.8. Other non-pharmacological interventions -- 4. Structural MRI changes in TRD -- 4.1. Brain volume and grey matter integrity in TRD -- 4.2. White matter integrity in TRD -- 4.3. The relationship between structural changes, TRD symptoms, illness duration, and treatment interventions -- 5. MRS and TRD -- 5.1. Neurotransmitter levels in TRD at baseline -- 5.2. Non-pharmacological interventions -- 5.3. Pharmacological interventions -- 6. Insights, challenges, and future steps -- Conflict of interest -- Funding -- Acknowledgments -- References -- Chapter 6: Next generation antidepressants with novel mechanisms for treatment resistant depression -- Abstract -- Keywords -- 1. Traditional antidepressants in major depressive disorder treatment and their limitations -- 2. Consciousness, neuroplasticity, depression, and antidepressants (Fig. 1) -- 3. Consciousness and monoamine neurotransmitters (Fig. 1) -- 4. Altered consciousness and rapid-acting antidepressant effect: Based on the evidence of ketamine and psilocybin -- 5. Molecular and neuroimaging mechanisms of the antidepressant effect of ketamine and psilocybin (Fig. 2) -- 6. Ongoing clinical trials of rapid-acting antidepressant drug candidates -- 7. Conclusion -- References. | |
| 505 | 8 | |a Chapter 7: Psychological aspects and psychotherapy for TRD -- Abstract -- Keywords -- 1. Psychological aspects for treatment-resistant depression -- 2. Psychotherapy for TRD -- 2.1. Cognitive-behavioral therapy -- 2.2. Interpersonal therapy -- 2.3. Psychodynamic therapy -- 2.4. Mindfulness-based cognitive therapy -- 2.5. Acceptance and commitment therapy -- 2.6. Dialectical behavior therapy -- 2.7. Psychotherapeutic difficulties in treating TRD -- 3. Conclusion -- References. | |
| 504 | |a Includes bibliographical references and index. | ||
| 520 | |a Major depressive disorder (MDD) is a common but deteriorating illness worldwide with high comorbidity. The World Health Organization has estimated that MDD would be the leading cause of human disability by 2030. However, many patients with depression fail to respond to antidepressant treatment. Such treatment-resistant depression (TRD) is associated with worse clinical outcomes, higher suicidality, and a huge socioeconomic burden. However, many unresolved issues have been noted, including different terms used for TRD, definition of an adequate antidepressant trial (standard or maximal dosage, duration of an antidepressant treatment, etc.), a lack of consensus on a consistent TRD definition, and so forth. Furthermore, TRD could occur in different age groups, and patients with TRD may suffer from the cooccurrence of many refractory somatic or physical symptoms, such as insomnia, headache, and tinnitus. Although psychosocial stressors are associated with TRD, biological factors also play an important role in its central mechanisms. For example, functional abnormalities in the mood circuits, neuroinflammation, dysregulation in the brain-gut axis, abnormal brain glutamatergic neurotransmissions, and even genetic predispositions are all involved. For a long time, electroconvulsive therapy has been considered effective in TRD, but its use is declining given its potential side effects during or along with the procedures. Many newer forms of treatment options, such as brain stimulation, next-generation antidepressants (e.g., glutamatergic rapid-acting antidepressants and certain psychedelics) are available for treating TRD. To provide a better treatment for TRD, psychological intervention is also critical, and for some chronic or highly refractory patients, psychiatric rehabilitation could be the key to fewer relapses of depressive episodes and better quality of life. | ||
| 588 | |a Description based on online resource; title from digital title page (viewed on August 21, 2023). | ||
| 650 | 0 | |a Depression, Mental |x Treatment. | |
| 700 | 1 | |a Cheng, Chih-Ming. | |
| 776 | 0 | 8 | |i Print version: |a Li, Cheng-Ta |t Treatment-Resistant Depression |d San Diego : Elsevier,c2023 |z 9780323957786 |
| 830 | 0 | |a Progress in brain research ; |v v. 278. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/bookseries/00796123/278 |z Texto completo |
| 880 | 8 | |6 505-00/(S |a 2.2. Fecal microbiota transplantation -- 3. The vagus nerve in the brain-gut axis and vagus nerve stimulation -- 3.1. Role of the vagus nerve in depression-like behaviors in rodents -- 3.2. Vagus nerve stimulation for treatment-resistant depression -- 4. Effects of ketamine and its enantiomers for treatment-resistant depression -- 4.1. Rapid-acting antidepressant actions of (R,S)-ketamine in patients with treatment-resistant depression -- 5. Conclusions -- Acknowledgments -- Declaration of competing interest -- References -- Chapter 4: Molecular imaging findings for treatment resistant depression -- Abstract -- Keywords -- 1. Background -- 2. PET and SPECT findings for the neurobiology of TRD -- 2.1. Regional cerebral blood flow studies for TRD -- 2.2. Fluorodeoxyglucose studies for TRD -- 2.3. Monoamine studies for TRD -- 2.4. β-amyloid studies for TRD -- 2.5. Microglia studies for TRD -- 3. PET and SPECT findings for the treatment of TRD -- 3.1. Electroconvulsive therapy for TRD -- 3.2. Transcranial magnetic stimulation for TRD -- 3.2.1. rCBF studies for transcranial magnetic stimulation for TRD -- 3.2.2. FDG studies for transcranial magnetic stimulation for TRD -- 3.2.3. Dopamine studies for transcranial magnetic stimulation for TRD -- 3.3. Vagus nerve stimulation for TRD -- 3.4. Deep brain stimulation for TRD -- 3.5. Ketamine for TRD -- 3.6. Other treatments for TRD -- 4. Summary of PET and SPECT findings for TRD -- 4.1. Anterior cingulate gyrus/medial prefrontal cortex -- 4.2. Prefrontal cortex -- 4.3. Insula -- 4.4. Hippocampus/amygdala -- 4.5. Parahippocampus -- 4.6. Striatum -- 5. Future directions -- 5.1. Molecular imaging for specific neural substrates in TRD -- 5.2. Multimodal imaging approaches for TRD -- 5.3. Open data and analysis pipelines -- 6. Conclusions -- References. | |